Clinical Trial

Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Major objectives to evaluate the efficacy and safety of lparomlimab and Tuvonralimab Injection ((QL1706, an Anti-PD-1/CTLA-4 Combined Antibody)) combined with SBRT in patients with early-stage non-small cell lung cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-01-23; most recent amendment 2026-04-27.
Trial Details
NCT Number NCT07379398
Lead Sponsor Tianjin Medical University Cancer Institute and Hospital
Conditions NSCLC
Enrollment 28 participants
Start Date 2026-04-01
Primary Completion 2029-06-30 (estimated)
Study Completion 2031-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-29